Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Burman

Nurse Practitioner, Family Minot, ND Nurse Practitioner

NPI 1083137756 CMS profile 10414350

1500 21St Ave Nw Ste 101, Minot, ND 58703

Open in the dashboard

General payments

$3,400

247 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Burman of Minot, ND is reported in the CMS Open Payments database as having received $3,400 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $931 64
2024 General $906 69
2023 General $760 52
2022 General $525 42
2021 General $280 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Burman
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jennifer Burman were reported at $931. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jennifer Burman Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $280 $124 $35–$379 $132
2022 $525 $141 $44–$430 $149
2023 $760 $154 $49–$476 $160
2024 $906 $165 $51–$504 $164
2025 $931 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $786 54 payments
  2. Lilly USA, LLC $653 55 payments
  3. Novo Nordisk Inc $552 48 payments
  4. Amgen Inc. $547 40 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $120 7 payments
  6. Exact Sciences Corporation $95 6 payments
  7. Novartis Pharmaceuticals Corporation $54 4 payments
  8. Abbott Laboratories $52 2 payments
  9. GlaxoSmithKline, LLC. $48 3 payments
  10. E.R. Squibb & Sons, L.L.C. $48 3 payments
  11. Other $445 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,400 247 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $516 35 payments
  2. Ozempic $489 39 payments
  3. RYBELSUS $489 39 payments
  4. MOUNJARO $469 38 payments
  5. EVENITY $397 27 payments
  6. Prolia $336 23 payments
  7. QULIPTA $317 21 payments
  8. VRAYLAR $207 14 payments
  9. Otezla $150 13 payments
  10. JARDIANCE $130 13 payments
  11. Other $1,361 90 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,451

Median for Nurse Practitioner: 389

Drug cost

$76,026

Median for Nurse Practitioner: $21,885

Branded share of claims

22.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 20 $37,803
Eliquis Apixaban Brand 13 $16,213
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $1,852
Levothyroxine Sodium Generic 100 $1,232
Metformin Hcl Er Metformin Hcl Brand 70 $1,208
Synthroid Levothyroxine Sodium Brand 11 $1,198
Atorvastatin Calcium Generic 123 $1,188
Ventolin Hfa Albuterol Sulfate Brand 18 $1,036
Metoprolol Succinate Generic 53 $1,026
Omeprazole Generic 60 $987

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$23,200

Of which drugs: $9,793

Medicare patients

92

Average age 68

Services billed

577

48 women, 44 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 34%
Depression 29%
Diabetes 28%
Chronic kidney disease 21%
Heart failure 15%
Ischemic heart disease 14%
COPD 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 14 17 $2,451
Vaccine for influenza for injection into muscle 90662 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $109
$109 — —
QULIPTA
  • AbbVie, Inc. $109
$109 — —
MOUNJARO
  • Lilly USA, LLC $106
$106 — —
RYBELSUS
  • Novo Nordisk Inc $68
$68 — —
Ozempic
  • Novo Nordisk Inc $68
$68 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record